Stem Cells Live: Characterising the cell phenome: how to define our cell therapy products.

Many interesting and difficult questions were raised in Tuesday’s round table discussion on production and manufacture hosted by Jim Reid chairman of Sistemic U.K. The topic of this open discussion was ‘What is the role of improved product characterisation on the development and approval of cell therapy product?’. Morrie Ruffin of the US alliance for regenerative medicine (ARM) kicked of …